1
|
Cong X, Zhuo Q, Hao N, Mishra A, Nishiura M, Hou Z. Divergent Synthesis of Multi-Substituted Aminotetralins via [4+2] Annulation of Aldimines with Alkenes by Rare-Earth-Catalyzed Benzylic C(sp 3 )-H Activation. Angew Chem Int Ed Engl 2024; 63:e202318203. [PMID: 38226440 DOI: 10.1002/anie.202318203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 01/12/2024] [Accepted: 01/15/2024] [Indexed: 01/17/2024]
Abstract
The search for efficient and selective methods for the divergent synthesis of multi-substituted aminotetralins is of much interest and importance. We report herein for the first time the diastereoselective [4+2] annulation of 2-methyl aromatic aldimines with alkenes via benzylic C(sp3 )-H activation by half-sandwich rare-earth catalysts, which constitutes an efficient route for the divergent synthesis of both trans and cis diastereoisomers of multi-substituted 1-aminotetralin derivatives from readily accessible aldimines and alkenes. The use of a scandium catalyst bearing a sterically demanding cyclopentadienyl ligand such as C5 Me4 SiMe3 or C5 Me5 exclusively afforded the trans-selective annulation products in the reaction of aldimines with styrenes and aliphatic alkenes. In contrast, the analogous yttrium catalyst, whose metal ion size is larger than that of scandium, yielded the cis-selective annulation products. This protocol features 100 % atom-efficiency, excellent diastereoselectivity, broad substrate scope, and good functional group compatibility. The reaction mechanisms have been elucidated by kinetic isotope effect (KIE) experiments and the isolation and transformations of some key reaction intermediates.
Collapse
Affiliation(s)
- Xuefeng Cong
- Advanced Catalysis Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Qingde Zhuo
- Organometallic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Na Hao
- Advanced Catalysis Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Aniket Mishra
- Advanced Catalysis Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Masayoshi Nishiura
- Advanced Catalysis Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Organometallic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Zhaomin Hou
- Advanced Catalysis Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Organometallic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
2
|
Dreger A, Kharwb O, Agoglitta O, Bülbül EF, Melesina J, Sippl W, Holl R. Chiral Pool Synthesis, Biological Evaluation and Molecular Docking Studies ofC‐Furanosidic LpxC Inhibitors. ChemMedChem 2019; 14:871-886. [DOI: 10.1002/cmdc.201900068] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Indexed: 01/15/2023]
Affiliation(s)
- Alexander Dreger
- Department of Chemistry, Institute of Organic ChemistryUniversity of Hamburg Martin-Luther-King Platz 6 20146 Hamburg Germany
- German Center for Infection Research (DZIF), partner site Hamburg-Lübeck-Borstel-Riems Germany
| | - Omar Kharwb
- Institute of Pharmaceutical and Medicinal ChemistryUniversity of Münster Corrensstr. 48 48149 Münster Germany
| | - Oriana Agoglitta
- Department of Chemistry, Institute of Organic ChemistryUniversity of Hamburg Martin-Luther-King Platz 6 20146 Hamburg Germany
- German Center for Infection Research (DZIF), partner site Hamburg-Lübeck-Borstel-Riems Germany
- NRW Graduate School of ChemistryUniversity of Münster Germany
| | - Emre F. Bülbül
- Institute of PharmacyMartin Luther University of Halle-Wittenberg Wolfgang-Langenbeck Str. 4 06120 Halle/Saale Germany
| | - Jelena Melesina
- Institute of PharmacyMartin Luther University of Halle-Wittenberg Wolfgang-Langenbeck Str. 4 06120 Halle/Saale Germany
| | - Wolfgang Sippl
- Institute of PharmacyMartin Luther University of Halle-Wittenberg Wolfgang-Langenbeck Str. 4 06120 Halle/Saale Germany
| | - Ralph Holl
- Department of Chemistry, Institute of Organic ChemistryUniversity of Hamburg Martin-Luther-King Platz 6 20146 Hamburg Germany
- German Center for Infection Research (DZIF), partner site Hamburg-Lübeck-Borstel-Riems Germany
| |
Collapse
|
3
|
Zhao C, Rakesh KP, Ravidar L, Fang WY, Qin HL. Pharmaceutical and medicinal significance of sulfur (S VI)-Containing motifs for drug discovery: A critical review. Eur J Med Chem 2019; 162:679-734. [PMID: 30496988 PMCID: PMC7111228 DOI: 10.1016/j.ejmech.2018.11.017] [Citation(s) in RCA: 279] [Impact Index Per Article: 55.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 10/17/2018] [Accepted: 11/07/2018] [Indexed: 01/04/2023]
Abstract
Sulfur (SVI) based moieties, especially, the sulfonyl or sulfonamide based analogues have showed a variety of pharmacological properties, and its derivatives propose a high degree of structural diversity that has established useful for the finding of new therapeutic agents. The developments of new less toxic, low cost and highly active sulfonamides containing analogues are hot research topics in medicinal chemistry. Currently, more than 150 FDA approved Sulfur (SVI)-based drugs are available in the market, and they are widely used to treat various types of diseases with therapeutic power. This comprehensive review highlights the recent developments of sulfonyl or sulfonamides based compounds in huge range of therapeutic applications such as antimicrobial, anti-inflammatory, antiviral, anticonvulsant, antitubercular, antidiabetic, antileishmanial, carbonic anhydrase, antimalarial, anticancer and other medicinal agents. We believe that, this review article is useful to inspire new ideas for structural design and developments of less toxic and powerful Sulfur (SVI) based drugs against the numerous death-causing diseases.
Collapse
Affiliation(s)
- Chuang Zhao
- Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan, 430070, PR, China
| | - K P Rakesh
- Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan, 430070, PR, China.
| | - L Ravidar
- Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan, 430070, PR, China
| | - Wan-Yin Fang
- Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan, 430070, PR, China
| | - Hua-Li Qin
- Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan, 430070, PR, China.
| |
Collapse
|
4
|
Abstract
INTRODUCTION Kinins are peptide mediators exerting their pro-inflammatory actions by the selective stimulation of two distinct G-protein coupled receptors, termed BKB1R and BKB2R. While BKB2R is constitutively expressed in a multitude of tissues, BKB1R is hardly expressed at baseline but highly inducible by inflammatory mediators. In particular, BKB1R was shown to be involved in the pathogenesis of numerous inflammatory diseases. Areas covered: This review intends to evaluate the therapeutic potential of substances interacting with the BKB1R. To this purpose we summarize the published literature on animal studies with antagonists and knockout mice for this receptor. Expert Opinion: In most cases the pharmacological inhibition of BKB1R or its genetic deletion was beneficial for the outcome of the disease in animal models. Therefore, several companies have developed BKB1R antagonists and tested them in phase I and II clinical trials. However, none of the developed BKB1R antagonists was further developed for clinical use. We discuss possible reasons for this failure of translation of preclinical findings on BKB1R antagonists into the clinic.
Collapse
Affiliation(s)
- Fatimunnisa Qadri
- a Max-Delbrück Center for Molecular Medicine (MDC) , Berlin , Germany
| | - Michael Bader
- a Max-Delbrück Center for Molecular Medicine (MDC) , Berlin , Germany.,b Berlin Institute of Health (BIH) , Berlin , Germany.,c Charité University Medicine Berlin , Germany.,d German Center for Cardiovascular Research (DZHK) site Berlin , Berlin , Germany.,e Institute for Biology , University of Lübeck , Lübeck , Germany
| |
Collapse
|
5
|
Lupala CS, Gomez-Gutierrez P, Perez JJ. New insights into the stereochemical requirements of the bradykinin B1 receptor antagonists binding. J Mol Graph Model 2016; 68:184-196. [PMID: 27469392 DOI: 10.1016/j.jmgm.2016.06.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Revised: 06/17/2016] [Accepted: 06/17/2016] [Indexed: 02/01/2023]
Abstract
Bradykinin (BK) is a nonapeptide involved in several pathophysiological conditions including among others, septic and haemorrhagic shock, anaphylaxis, arthritis, rhinitis, asthma, inflammatory bowel disease. Accordingly, BK antagonists have long been sought after for therapeutic intervention. Action of BK is mediated through two different G-protein coupled receptors known as B1 and B2. Although there are several B1 antagonists reported in literature, their pharmacological profile is not yet optimal so that new molecules need to be discovered. In the present work we have constructed an atomistic model of the B1 receptor and docked diverse available non-peptide antagonists in order to get a deeper insight into the structure-activity relationships involving binding to this receptor. The model was constructed by homology modeling using the chemokine CXC4 and bovine rhodopsin receptors as template. The model was further refined using molecular dynamics for 600ns with the protein embedded in a POPC bilayer. From the refinement process we obtained an average structure that was used for docking studies using the Glide software. Antagonists selected for the docking studies include Compound 11, Compound 12, Chroman28, SSR240612, NPV-SAA164 and PS020990. The results of the docking study underline the role of specific receptor residues in ligand binding. The results of this study permitted to define a pharmacophore that describes the stereochemical requirements of antagonist binding, and can be used for the discovery of new compounds.
Collapse
Affiliation(s)
- Cecylia S Lupala
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain
| | - Patricia Gomez-Gutierrez
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain
| | - Juan J Perez
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain.
| |
Collapse
|
6
|
Wang Y, Kirschner A, Fabian AK, Gopalakrishnan R, Kress C, Hoogeland B, Koch U, Kozany C, Bracher A, Hausch F. Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control. J Med Chem 2013; 56:3922-35. [PMID: 23647266 DOI: 10.1021/jm400087k] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The design of efficient ligands remains a key challenge in drug discovery. In the quest for lead-like ligands for the FK506-binding protein 51 (FKBP51), we designed two new classes of bicyclic sulfonamides to probe the contribution of conformational energy in these ligands. The [4.3.1] scaffold had consistently higher affinity compared to the [3.3.1] or monocyclic scaffolds, which could be attributed to better preorganization of two key recognition motifs. Surprisingly, the binding of the rigid [4.3.1] scaffold was enthalpy-driven and entropically disfavored compared to the flexible analogues. Cocrystal structures at atomic resolution revealed that the sulfonamide nitrogen in the bicyclic scaffolds can accept an unusual hydrogen bond from Tyr(113) that mimics the putative FKBP transition state. This resulted in the first lead-like, functionally active ligand for FKBP51. Our work exemplifies how atom-efficient ligands can be achieved by careful conformational control even in very open and thus difficult binding sites such as FKBP51.
Collapse
Affiliation(s)
- Yansong Wang
- AG Chemical Genomics, Max Planck Institute of Psychiatry , Kraepelinstraße 2, 80804 Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Rh(II)-Cp∗–TsDPEN catalyzed aqueous asymmetric transfer hydrogenation of chromenones into saturated alcohol: CC and CO reduction in one step. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.04.050] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency. Bioorg Med Chem Lett 2012; 22:1061-7. [DOI: 10.1016/j.bmcl.2011.11.112] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2011] [Revised: 11/23/2011] [Accepted: 11/28/2011] [Indexed: 11/23/2022]
|
9
|
Biswas K, Peterkin TAN, Bryan MC, Arik L, Lehto SG, Sun H, Hsieh FY, Xu C, Fremeau RT, Allen JR. Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists. J Med Chem 2011; 54:7232-46. [DOI: 10.1021/jm200808v] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Kaustav Biswas
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Tanya A. N. Peterkin
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Marian C. Bryan
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Leyla Arik
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Sonya G. Lehto
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Hong Sun
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Feng-Yin Hsieh
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Cen Xu
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert T. Fremeau
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jennifer R. Allen
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
10
|
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation. Bioorg Med Chem Lett 2011; 21:3384-9. [DOI: 10.1016/j.bmcl.2011.03.115] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2011] [Revised: 03/28/2011] [Accepted: 03/31/2011] [Indexed: 11/20/2022]
|
11
|
Utczás M, Székely E, Tasnádi G, Monek É, Vida L, Forró E, Fülöp F, Simándi B. Kinetic resolution of 4-phenyl-2-azetidinone in supercritical carbon dioxide. J Supercrit Fluids 2011. [DOI: 10.1016/j.supflu.2010.10.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Huang H, Player MR. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. J Med Chem 2010; 53:5383-99. [PMID: 20369879 DOI: 10.1021/jm1000776] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Hui Huang
- Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19477-0776, USA
| | | |
Collapse
|
13
|
Liu Q, Qian W, Li A, Biswas K, Chen JJ, Fotsch C, Han N, Yuan C, Arik L, Biddlecome G, Johnson E, Kumar G, Lester-Zeiner D, Ng GY, Hungate RW, Askew BC. Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonists. Bioorg Med Chem Lett 2010; 20:4593-7. [PMID: 20573508 DOI: 10.1016/j.bmcl.2010.06.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Revised: 05/28/2010] [Accepted: 06/02/2010] [Indexed: 11/17/2022]
Abstract
The bradykinin B1 receptor has been shown to mediate pain response and is rapidly induced upon injury. Blocking this receptor may provide a promising treatment for inflammation and pain. We previously reported tetralin benzyl amines as potent B1 antagonists. Here we describe the synthesis and SAR of B1 receptor antagonists with homobenzylic amines. The SAR of different linkers led to the discovery of tetralin allylic amines as potent and selective B1 receptor antagonists (hB1 IC(50)=1.3 nM for compound 16). Some of these compounds showed modest oral bioavailability in rats.
Collapse
Affiliation(s)
- Qingyian Liu
- Chemistry Research and Discovery, Amgen Inc., Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Fincham CI, Bressan A, Paris M, Rossi C, Fattori D. Bradykinin receptor antagonists – a review of the patent literature 2005 – 2008. Expert Opin Ther Pat 2009; 19:919-41. [DOI: 10.1517/13543770902994389] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
15
|
An efficient new enzymatic method for the preparation of β-aryl-β-amino acid enantiomers. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/j.tetasy.2008.08.009] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
16
|
Aryl sulfones as novel Bradykinin B1 receptor antagonists for treatment of chronic pain. Bioorg Med Chem Lett 2008; 18:4764-9. [DOI: 10.1016/j.bmcl.2008.07.108] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2008] [Revised: 07/23/2008] [Accepted: 07/28/2008] [Indexed: 11/22/2022]
|
17
|
Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists. Bioorg Med Chem Lett 2008; 18:4477-81. [DOI: 10.1016/j.bmcl.2008.07.055] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2008] [Revised: 07/09/2008] [Accepted: 07/14/2008] [Indexed: 11/19/2022]
|
18
|
Chen JJ, Biswas K. Small molecule bradykinin B1 receptor antagonists as potential therapeutic agents for pain. PROGRESS IN MEDICINAL CHEMISTRY 2008; 46:173-204. [PMID: 18381126 DOI: 10.1016/s0079-6468(07)00004-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Affiliation(s)
- Jian Jeffrey Chen
- Chemistry Research and Discovery, Amgen Inc., MS 29-1-B, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
| | | |
Collapse
|
19
|
Biswas K, Li A, Chen JJ, D'Amico DC, Fotsch C, Han N, Human J, Liu Q, Norman MH, Riahi B, Yuan C, Suzuki H, Mareska DA, Zhan J, Clarke DE, Toro A, Groneberg RD, Burgess LE, Lester-Zeiner D, Biddlecome G, Manning BH, Arik L, Dong H, Huang M, Kamassah A, Loeloff R, Sun H, Hsieh FY, Kumar G, Ng GY, Hungate RW, Askew BC, Johnson E. Potent Nonpeptide Antagonists of the Bradykinin B1 Receptor: Structure−Activity Relationship Studies with Novel Diaminochroman Carboxamides. J Med Chem 2007; 50:2200-12. [PMID: 17408249 DOI: 10.1021/jm070055c] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The bradykinin B1 receptor is induced following tissue injury and/or inflammation. Antagonists of this receptor have been studied as promising candidates for treatment of chronic pain. We have identified aryl sulfonamides containing a chiral chroman diamine moiety that are potent antagonists of the human B1 receptor. Our previously communicated lead, compound 2, served as a proof-of-concept molecule, but suffered from poor pharmacokinetic properties. With guidance from metabolic profiling, we performed structure-activity relationship studies and have identified potent analogs of 2. Variation of the sulfonamide moiety revealed a preference for 3- and 3,4-disubstituted aryl sulfonamides, while bulky secondary and tertiary amines were preferred at the benzylic amine position for potency at the B1 receptor. Modifying the beta-amino acid core of the molecule lead to the discovery of highly potent compounds with improved in vitro pharmacokinetic properties. The most potent analog at the human receptor, compound 38, was also active in a rabbit B1 receptor cellular assay. Furthermore, compound 38 displayed in vivo activity in two rabbit models, a pharmacodynamic model with a blood pressure readout and an efficacy model of inflammatory pain.
Collapse
Affiliation(s)
- Kaustav Biswas
- Department of Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|